Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERYC 125 vs BIAXIN XL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-t RNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Treatment of infections caused by susceptible strains of microorganisms (e.g., respiratory tract infections, skin infections, pertussis, diphtheria, syphilis),Off-label: Prokinetic agent for gastroparesis, treatment of delayed gastric emptying
Acute bacterial exacerbation of chronic obstructive pulmonary disease,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis caused by Streptococcus pyogenes,Uncomplicated skin and skin structure infections,Mycobacterium avium complex infection (prevention and treatment),Helicobacter pylori infection (in combination with other drugs)
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
500 mg orally once daily for 7 to 14 days
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
Primarily hepatic via cytochrome P450 3A4 (CYP3A4) isoenzyme; undergoes demethylation and hydrolysis; major metabolite is desosamine.
Primarily metabolized by the cytochrome P450 system, mainly CYP3A4, to active metabolites such as 14-hydroxyclarithromycin.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
70-90% bound to albumin and alpha-1-acid glycoprotein.
Approximately 70% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
0.5-0.9 L/kg; indicates distribution into total body water with some tissue binding.
Volume of distribution is 3-4 L/kg, indicating extensive tissue penetration (e.g., lungs, sinuses, tonsils).
Oral: ~35% (acid-labile, enteric-coated).
Oral bioavailability is approximately 50% due to first-pass metabolism; food does not significantly affect the extended-release formulation.
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce dose by 50% or extend interval to every 8-12 hours.
Cr Cl <30 m L/min: 500 mg orally once daily or 250 mg twice daily. Cr Cl <30 m L/min not recommended for BIAXIN XL due to decreased clearance.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: reduce dose by 75% or avoid use.
Child-Pugh Class C: reduce dose by 50% or consider alternative therapy. Child-Pugh Class A or B: no adjustment necessary.
30-50 mg/kg/day orally divided every 6-8 hours; maximum 2 g/day.
Not approved for use in children less than 12 years of age. For children ≥12 years: same as adult dosing.
No specific adjustment; monitor for ototoxicity and QT prolongation; consider lower initial dose due to age-related renal decline.
Increased risk of QT prolongation. Monitor renal function and consider dose adjustment based on creatinine clearance. No specific dose adjustment is recommended solely for age.
No FDA boxed warning for ERYC 125.
No FDA boxed warning.
Risk of QT prolongation and ventricular arrhythmias (e.g., torsades de pointes), especially with other QT-prolonging drugs or electrolyte abnormalities,Hepatic impairment: monitor liver function,Potential for drug interactions via CYP3A4 inhibition,May exacerbate myasthenia gravis,Infantile hypertrophic pyloric stenosis (IHPS) risk in neonates
Increased risk of cardiac arrhythmias (QT prolongation, torsades de pointes) in patients with pre-existing cardiac conditions or electrolyte abnormalities,Hepatotoxicity, including hepatic failure and jaundice,Exacerbation of myasthenia gravis symptoms,Increased risk of colchicine toxicity when used with P-glycoprotein inhibitors,Potential for drug interactions due to CYP3A4 inhibition
Hypersensitivity to erythromycin or any macrolide antibiotic,Concomitant use with CYP3A4 substrates that prolong QT interval (e.g., terfenadine, astemizole, cisapride, pimozide),Pre-existing QT prolongation or cardiac arrhythmia history
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic,Concomitant use with ergotamine or dihydroergotamine,Concomitant use with HMG-Co A reductase inhibitors that are extensively metabolized by CYP3A4 (e.g., lovastatin, simvastatin),Concomitant use with pimozide,History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use,QTc prolongation or cardiac arrhythmia history (relative contraindication)
Grapefruit and grapefruit juice should be avoided as they can increase drug levels and risk of toxicity. Food does not significantly alter absorption of the ethylsuccinate formulation, but taking with a high-fat meal may slightly delay absorption. Avoid alcohol as it may increase risk of hepatotoxicity.
Take with food to enhance absorption and reduce GI intolerance. Avoid grapefruit and grapefruit juice as they may alter drug metabolism. No other significant food interactions.
Erythromycin, including ERYC 125, has not been associated with major congenital malformations in human studies. However, there is a potential increased risk of pyloric stenosis in infants exposed in utero or postnatally. No known teratogenic effects in first trimester; use in pregnancy is generally considered safe when indicated, especially for infections like chlamydia or syphilis.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal malformations. Second and third trimesters: No known fetal risks from limited human studies; however, due to rare reports of pyloric stenosis in infants exposed to macrolides late in pregnancy, consider risk-benefit. Overall, use only if clearly needed.
Erythromycin is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. It is considered compatible with breastfeeding by the American Academy of Pediatrics, but may increase the risk of pyloric stenosis in neonates. Monitor for gastrointestinal symptoms in the infant.
Clarithromycin is excreted into breast milk. M/P ratio is approximately 1.0 (based on total drug). Consider the potential for infant gastrointestinal effects (diarrhea, candidiasis) and theoretical risk of antibiotic-associated colitis. Compatible with breastfeeding with monitoring for adverse effects in the infant.
No specific dose adjustment is required for pregnancy based on pharmacokinetic changes. However, erythromycin has reduced plasma concentrations in late pregnancy due to increased volume of distribution and clearance, but no dose adjustment is recommended. Standard dosing is used.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes (increased volume of distribution, altered clearance) may occur, but clinical significance is not established. Use standard adult dosing with caution.
ERYC 125 (erythromycin ethylsuccinate) is a macrolide antibiotic; note that it may prolong QT interval, especially when combined with other QT-prolonging drugs. Avoid use in patients with hepatic impairment or known cholestatic jaundice. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption, but food does not significantly affect the ethylsuccinate formulation.
BIAXIN XL (clarithromycin extended-release) is a macrolide antibiotic with a long half-life allowing once-daily dosing. It is a strong CYP3A4 inhibitor, increasing levels of many drugs including statins, warfarin, and oral contraceptives. Prolongs QT interval; avoid in patients with known QTc prolongation or concurrent use of other QT-prolonging agents. Common adverse effects include metallic taste and gastrointestinal upset. Monitor liver function in hepatic impairment.
Take exactly as prescribed; do not skip doses or stop early even if you feel better.,Take this medication on an empty stomach, at least 1 hour before or 2 hours after a meal.,Avoid grapefruit and grapefruit juice while taking this medicine.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe stomach pain.,Notify your doctor immediately if you experience irregular heartbeat, fainting, or severe diarrhea.,Complete the full course to prevent antibiotic resistance.
Take with food to reduce stomach upset.,Do not crush or chew the tablet; swallow whole.,Complete the full course even if you feel better.,Avoid alcohol during treatment.,Inform your doctor about all medications, including OTC and herbal supplements, due to drug interactions.,Report symptoms of arrhythmia (dizziness, palpitations, fainting) or severe diarrhea.,May cause metallic taste; this is temporary.,Use alternate contraception if on oral contraceptives due to interaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERYC 125 vs BIAXIN XL, answered by our medical review team.
ERYC 125 is a Macrolide Antibiotic that works by Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-t RNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.. BIAXIN XL is a Macrolide Antibiotic that works by Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERYC 125 and BIAXIN XL depend on the specific clinical indication. These are both Macrolide Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERYC 125 is: 250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.. The standard adult dose of BIAXIN XL is: 500 mg orally once daily for 7 to 14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERYC 125 and BIAXIN XL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERYC 125 is classified as Category C. Erythromycin, including ERYC 125, has not been associated with major congenital malformations in human studies. However, there is a potential increased risk of pyloric stenosis in . BIAXIN XL is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.